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Abstract
Rationale Trust is a key component of social interactions. In order to assess the trustworthiness of others, people rely on both
information learned from previous encounters, as well as on implicit biases associated with specific facial features.
Objective Here, we investigated the role of catecholamine (dopamine and noradrenaline) transmission on trust decisions as a
function of both experienced behavior and facial features.
Methods To increase catecholamine levels, methylphenidate (MPH, i.e., Ritalin®, 20 mg) was administered to partic-
ipants (N = 24) prior to their playing a well-studied economic task, namely the Trust Game (Berg et al. 1995). We
measured the amount of money invested with a variety of game partners. Across game partners, we manipulated two
aspects of trust: the facial trust level (high facial trust, low facial trust, and non-social) and the likelihood of recipro-
cation (high, low).
Results Results demonstrated no main effect of MPH on investments, but rather a selective lowering of investments under MPH
as compared with placebo with the game partners who were low on facial trustworthiness and were low reciprocators.
Conclusion These results provide evidence that MPH administration impacts social trust decision-making, but does so in a
context-specific manner.
Keywords Methylphenidate . Ritalin . Trust Game . Trust . Social learning . Decision-making . Catecholamines
Introduction
We engage in decision-making on a daily basis: from relative-
ly unimportant choices, such as deciding what to wear on a
particular day, to ones of greater consequence, such as wheth-
er to accept a particular job offer. Though some of our
decisions are made outside of any specific social context
(e.g., what songs to put on a workout playlist), many of our
choices consider, to a greater or lesser extent, the feelings,
beliefs, expectations, and behaviors of our social partners
(e.g., choosing a Christmas present for a friend).
These latter social choices are well exemplified by the de-
cision to trust another person. Trust is often defined as the
willingness to rely on another individual, with the associated
risk of that trust being abused. To this end, deciding on wheth-
er a social partner is worthy of trust involves an estimation of
the likelihood of being betrayed. This important process is
typically studied experimentally using the Trust Game (Berg
et al. 1995), a well-characterized financial investment task that
allows the assessment of the various factors that can influence
trust decisions. Investment amounts in the Trust Game have
been shown to vary with several factors, such as knowledge
or beliefs about the moral character of the game partner
(Delgado et al. 2005a), perceived trustworthiness of the
game partner (Van ‘t Wout and Sanfey 2008), experienced
behavior (King-Casas et al. 2005, Krueger et al. 2007), and
expectations about general investment patterns in the Trust
Game (Chang and Sanfey 2013).
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In essence, trust decisions are concerned with the assess-
ment of beliefs about a partner’s future behavior. Previous
literature has shown that trust decisions are often reliant on
information about the past behavior of our interaction partner,
such as reputation (Axelrod and Hamilton 1981; Delgado
et al. 2005a; King-Casas et al. 2005). In addition to using
past behavior to inform future behavior, inferences are made
about a person’s character based on invariant facial features,
such as the size of the eyes or the width of the cheekbones
(Winston et al. 2002; Willis and Todorov 2006). Research has
shown how both the facial features and the past behavior of a
social partner interact in order to construct trust beliefs (Chang
et al. 2010). This was demonstrated by employing a reinforce-
ment learning framework where social learning of trust
depended on rewards (i.e., the positive experience of trust
reciprocation) and punishments (i.e., the negative experience
of trust abuse). Thus, two key components of trust are the
ability to infer an initial impression of the reliability of others,
as well as the ability to learn from subsequent positive and
negative experiences.
Learning from rewards and punishments is well established
to depend on catecholamine transmission, and more specifi-
cally on striatal dopamine (DA) (Collins and Frank 2013).
Striatal DA has also been shown to modulate probabilistic
reinforcement learning (Bódi et al. 2009; Frank et al. 2004;
Pessiglione et al. 2006). Moreover, work from Doll et al.
(2011) has shown that DA can influence the degree to which
prior instructions and actual experience interact and bias
choice. However, whether these effects generalize into affect-
ing aspects of higher order social cognition has yet to be in-
vestigated. Here, we examine the effects of a catecholamine
challenge on trust-based decisions by assessing effects of
acute administration of a single oral dose of methylphenidate
(MPH) on performance in a repeated Trust Game.
MPH is a psychostimulant drug that efficiently elevates the
extracellular levels of DA in the striatum (Volkow et al. 2005)
as well as DA and noradrenaline (NA) in the prefrontal cortex.
It acts by blocking the DA and the NA transporter and thus
elevates catecholamine levels in the synapse. MPH has been
shown to increase affective and neural responses to reward in
healthy adults (Volkow et al. 2002), to potentiate learning
from reward versus punishment (Clatworthy et al. 2009; Tye
et al. 2010; Frank et al. 2011; van der Schaaf et al. 2013) and
to boost cognitive performance (Arnsten 2011; Swanson
et al. 2011). Thus, one potential route for MPH to impact trust
could be by modulating learning directly from rewards and
punishments respectively.
However, as noted above, trust involves more than just
learning from rewards and punishments. As shown by
Chang et al. (2010), a defining feature of trust is the use of
both current feedback as well as prior beliefs to inform future
behavior. Instructions or inferred moral character have a
strong effect on subsequent behavior and learning (Delgado
et al. 2005a, b; Doll et al. 2009). Therefore, MPH might also
impact trust decisions through altering initial beliefs about the
partner’s inherent moral character, which is often inferred di-
rectly from facial features. Doll et al. (2011) have shown that
the degree to which initial biases are strengthened by experi-
ence is linked to genetic dopaminergic gene variations.
Relatedly, ter Huurne et al. (2015) have demonstrated that
MPH increases the attention to faces over scrambled images,
making it plausible that these social factors may be enhanced
under MPH. Moreover, MPH has previously been found to
impact decision-making, particularly in a social context
(Campbell-Meiklejohn et al. 2012a). Therefore, another
potential route for MPH to impact trust could be via these
social factors.
Thus, we predict that MPHwill have an adaptive impact on
trust decisions. Specifically, we hypothesize that, in terms of
the likelihood of reciprocation of a given partner, there will be
a decrease in investments with low reciprocating partners and
an increase in investments with high reciprocators.
Additionally, we hypothesize that social factors may also play
a role, especially when interacting with a game partner for the
first time, in which case MPH could enhance the salience of
facial trustworthiness. Finally, as discussed above, a number
of studies have demonstrated that these two factors, learning
and facial trustworthiness, interact and therefore we will also
explore how MPH may modulate this interaction.
In order to investigate the role of catecholamines on trust,
we performed a double-blind, placebo-controlled, crossover
design. Following drug administration, participants played a
well-known economic task designed to quantify trust deci-
sions, namely the Trust Game (Berg et al. 1995). Our version
of this task enabled us to disentangle the influence of catechol-
amines on trust decisions that could be driven by two main
factors. The first, an initial social bias, was examined by
pairing participants with game partners who possessed differ-
ing levels of facial trustworthiness. The second, learning via
direct interaction, was explored by playing with partners who
demonstrated varying likelihoods of reciprocating the partici-
pant’s trust. Finally, and importantly, we investigated the in-
teraction of these two factors, in order to capture any
condition-specific effects.
Materials and methods
Participants Twenty-four students (11 men, M age = 20.60;
SD = 2.20) of the Radboud University participated in this ex-
periment. The participants gave written informed consent and
receivedmonetary reward in return for taking part in the study.
The study was approved by the local medical-ethical commit-
tee (Committee for Protection of Human Subjects of the
Arnhem/Nijmegen region; CMO protocol number 2010/283)
and adhered to the guidelines of the Declaration of Helsinki.
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Screening
All participants were healthy volunteers and had no relevant
history of medical or psychiatric conditions and no history of
drug abuse. Participants were not accepted in the study based
on the following criteria: fulfillment of ADHD criteria, family
history of schizophrenia, bipolar disorder, depression or neu-
rological abnormalities. They had to be currently free of over-
the-counter medication use, drink less than 20 units of alcohol,
and smoke less than 20 cigarettes per week. If cannabis was
used less than 2 weeks prior to testing or if there was a history
of frequent use of recreational drugs (more than 5 times week-
ly), the volunteers were not allowed to participate in the study.
During a first intake session, all participants were screened by
both a medical doctor and by a psychologist. This procedure
consisted of a physical examination of weight, heart rate and
blood pressure, a medical examination, and the Mini-
International Neuropsychiatric Interview (MINI) (Sheehan
et al. 1998).
Pharmacological manipulation
Awithin-subjects, double-blind, placebo-controlled crossover
design was employed. Participants were administered MPH
(Ritalin®, 20 mg) and placebo on two separate experimental
sessions, at least 1 week apart from each other. All participants
were asked to not consume alcohol or take any medication
24 h prior to testing and to not consume caffeine on the day
of testing. The current task was part of a larger protocol: it was
preceded by a functional magnetic resonance imaging (fMRI)
experiment and two short behavioral experiments reported
elsewhere (Fallon et al. 2017; van der Schaaf et al. 2013; ter
Huurne et al. 2015). The task was executed ~ 3 h after drug
intake and lasted for ~ 17 min. Although time of testing was
optimized for the preceding fMRI paradigm (Fallon et al.
2017), assessment of the current task coincided with the active
time window of drug effects (~ 4 h with peak plasma levels
1½ hour) (Volkow et al. 2002; Swanson and Volkow 2003).
The Trust Game paradigm
Figure 1a and b show the experimental task design. In order to
address our research question, we used a modified version of
the Trust Game. Participants played a repeated Trust Game in
the role of the Investor. There are two players in the game:
Investor and Trustee. The Investor is provided with a 10 Euro
endowment. From this endowment, they must choose how
much money they will send to the Trustee (any amount from
0 to 10 Euros, in increments of 1 Euro). The Investor keeps the
money not transferred. The money transferred is multiplied by
a factor of 4 by the experimenter, such that the Trustee re-
ceives this quadrupled amount. Finally, the Trustee decides
whether to send any money back to the Investor, with no
requirement that any money is returned. Several studies show
that, in a one-shot game, Investors send on average approxi-
mately half of their initial endowment (Camerer 2003).
Here, to investigate trust behavior across several interac-
tions, participants played a repeated version of the Trust
Game, meaning they had multiple exchanges with each of the
game partners. On each trial, participants first saw a photo of
their game partner on the screen, and then decided how much
money, if any, they would transfer to the respective partner.
Next, they received feedback about the decision of their partner,
with the amount transferred presented on the screen.
Within a trial, a fixation cross was first presented, followed
by the picture and the name of the partner for that round
(3000 ms). The participant could then decide how much they
wanted to transfer by pressing a button to increase the invest-
ment amount in 1 Euro increments. When the participant was
satisfied with their choice, they pressed a separate button to
confirm their investment. To ensure that the number of button
presses was orthogonal to the investment amount, the starting
investment value on the screen was randomly generated be-
tween 0 and 10. If the participant did not submit an offer
within 6000ms, they forfeited all of their money for the round.
The final feedback screen informed the participant whether
their game partner had shared or kept the money (which we
manipulated across trials, see below), also displaying the re-
spective amounts (4000 ms). The total length of a trial varied
between 13 and 16 s.
Dependent variableWe used the amount invested with a game
partner as the dependent variable. On each trial, a participant
could invest any amount from 0 to 10 Euros, in increments of
1 Euro.
Independent variables We assessed the effect of two factors
on trust behavior: the effect of prior social biases and the effect
of experience with a game partner. Importantly, we were par-
ticularly interested in the interaction of these two factors.
To investigate the effect of social biases on trust decisions,
we manipulated the type of partner with whom the participant
interacted. Participants played with two types of ostensible
human partners: one which was rated as high in facial trust-
worthiness and one rated as low in facial trustworthiness
(Oosterhof and Todorov 2008) (see details inGame partners).
Additionally, for examining the effect of social versus non-
social information on trustworthiness, participants also
interacted with a non-social partner, namely a slot machine.
To capture the effect of experience, we manipulated the
likelihood with which a partner would reciprocate trust—
participants played with three high reciprocity partners (two
human and one slot machine) and three low reciprocity part-
ners (also two human and one slot machine). Therefore, par-
ticipants interacted with a total of six game partners, namely:
one with high facial trust and high reciprocity, one with high
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facial trust and low reciprocity, one with low facial trust and
high reciprocity, one with low facial trust and low reciprocity,
one slot machine with high reciprocity, and one slot machine
with low reciprocity. If an offer was reciprocated, the game
partner always reciprocated by giving back half of the total
multiplied amount sent by the participant. When an offer was
not reciprocated, the game partner did not return any money to
the participant. On each trial, the game partner’s decision to
reciprocate was drawn from a distribution centered around a
probability of reciprocation of 75%. Similarly, in the low re-
ciprocation the decision to reciprocate was drawn from a dis-
tribution centered around a probability of reciprocation of
25%.
Both partner type and probability of reciprocation were
within-subject measures. Drug administration was a
within-subject factor, such that each participant was given
both placebo and MPH. The order in which these were
administered was counter-balanced, resulting in a
between-subject measure of order, either placebo-MPH
(12) or MPH-placebo (12).
Runs and trialsAs mentioned above, participants were test-
ed on two separate occasions: on one they were adminis-
tered MPH, on the other placebo. On each of these occa-
sions, participants completed a session of 72 trials of the
Trust Game, viewing another stimulus set of four faces
each time. Each experimental session was divided in three
runs, in which trials appeared evenly distributed in pseudo
random order. Overall, they played 12 times with each
game partner. Each run had a total of 24 trials, four trials
with each of the six game partners (two high-trust faces,
two low-trust faces, two slot machines).
Investor Trustee
€
I’m giving you 5 Euro.
Investor Trustee
€€ €€
The Trustee gets the amount 
sent by the Investor 
quadrupled.
Investor Trustee
€€€€
I’m giving you 
    half back.
This is Anna
You gave 
  6 Euro
    You gave
6 x 4 = 24 Euro
   You get 12 Euro
Anna kept 12 Euro
b)
a)
Fig. 1 a The Trust Game. There are two players in the game, Investor and
Trustee. The Investor is provided with a 10 Euro endowment. From this
endowment, the Investor must choose howmuch money they will send to
the Trustee, with this being any amount from 0 to 10 Euros, in increments
of 1 Euro. The money transferred is multiplied by a factor of 4 by the
experimenter, such that the Trustee receives this quadrupled amount.
Finally, the Trustee decides if they want to send any money back to the
Investor, with no requirement that any money is returned. b This
represents the time course of a single trial within the experiment. Each
square represents a screen. A fixation cross was shortly presented,
followed by the face and the name of the game partner for that trial
(3000 ms). The participant could then decide how much they wanted to
invest in the game partner, by pressing a button to increase the investment
amount in 1 Euro increments. When the participant was satisfied with
their choice, they pressed an additional button to finalize the investment.
If no offer was submitted in time (6000 ms), all of the money for the
round was forfeited. The final feedback screen informed the participant
whether their game partner had shared or kept the money. The length of a
trial varied between 13 and 16 s
1810 Psychopharmacology (2019) 236:1807–1816
Game partners The stimuli were eight frontal, colored photo-
graphic images of emotionally neutral faces and two pictures
of slot machines. Pictures showing faces were selected from a
standard set of 60 images (the Radboud Faces Database) and
were controlled for low-level visual features. The faces were
selected on the basis of trustworthiness ratings on a 7-point
Likert scale, which were given by 98 healthy subjects in a
pilot study. Since each participant underwent two experimen-
tal sessions, we used two different sets of pictures. Each set
consisted of four faces (two men, two women) and two slot
machines. The trustworthiness levels within each set were
matched such that one man and one woman had high trust-
worthiness (M = 5.20, SD = 0.76) and the other man and wom-
an had low trustworthiness ratings (M = 3.10, SD = 0.51). E-
Prime software (Psychology Software Tools, Inc., Pittsburgh,
PA) was used for stimulus presentation.
Statistical analysis
All behavioral data analyses were performed using the R sta-
tistical package, version 3.5.1 (R Development Core Team
2018) within RStudio, version 1.1.442.
We wanted to address several research questions. Firstly,
we were interested in testing whether MPH administration
impacts trust behavior overall, as measured by the mean
amount invested in the game partner. Secondly, we designed
our task specifically to explore whetherMPH could impact the
initial beliefs about the facial trust level of a partner.
Additionally, we wanted to compare whether there is a social
versus non-social effect of MPH. Thirdly, we included several
trials per game partner, together with two levels of reciproca-
tion. This allowed us to investigate whether the likelihood of
reciprocation has different effects on the amounts invested, as
a function of drug administration. Finally, we wanted to ad-
dress whether the facial trust factor interacts with the recipro-
cation factor, and if this effect responds differently to the cat-
echolamine challenge.
To address these questions, we ran a trial-by-trial mixed
effects model. The model was estimated using lme4 (Bates
et al. 2015), called using the lmer function of the package
lmerTest, version 2.0-36, in R. Our model had the following
fixed factors: drug administration (placebo, MPH), facial trust
level (high facial trust, low facial trust, slot machine), and
reciprocation level (high, low), together with all their interac-
tions. We had random intercepts per participant, and random
slopes for drug administration, game partner, and probability
of reciprocation (Baayen et al. 2008). Using mixed effects
models allowed us to best account for non-independence in
the data, without aggregating data points (i.e., investment de-
cisions) and thus reducing statistical power. Moreover, using
both random slopes and random intercepts within the mixed
effects models enabled us to consider individual variation in
the investment choices as a function of drug administration,
partner likelihood of reciprocation, and partner facial
trustworthiness.
Furthermore, we tested whether there were any order ef-
fects in our experiment, by adding the between subjects fixed
factor Border^ to the mixed model, to check for test-retest
effect of the iterated Trust Game. The single-shot Trust
Game has no test-retest effects. However, this repeated ver-
sion is designed specifically to trigger learning about the trust
behavior of the game partner. Optimal learning in this task
entails tracking of reciprocation probabilities and adjusting
the investment behavior accordingly.
For specifically investigating the effect of the initial beliefs
about trustworthiness and how MPH impacts that process, we
ran an ANOVA, using the ezANOVA function of the ez pack-
age, version 4.4-0. We used only the first game interaction
with each of the game partners (i.e., the first trial in each
condition). This served a double function: first, it ensured that
each partner type was treaded as intended (i.e., the faces that
were used as proxies for higher trustworthiness actually re-
ceived higher initial investments), and second, it allowed us
to investigate whether drug administration altered the percep-
tion of these facial features.
p values were computed using type II chi-square tests as
implemented in the ANOVA function. Post-hoc comparisons
were performed using the testInteractions function of the phia
package, version 0.2-1, and were Holm-corrected for multiple
comparisons.
Results
First trial
One set of analyses focused only on the first encounter (trial)
between participants and each of the game partners, to assess
whether facial trustworthiness alone had an impact on invest-
ment amounts, and whether methylphenidate modulated this
effect. We found a main effect of facial trustworthiness
expressed in an overall significant difference in mean invest-
ments on those trials (Facial Trust, F(2, 271) = 5.896, p =
0.003). Pairwise comparisons revealed significant differences
between all three types of facial trustworthiness: participants
invested more with high facial trust partners as compared to
low facial trust partners (M diff = 0.684; SE = 0.287; p =
0.026), and less with slot machine partners, as compared to
both high and low facial trust partners (MSlotVSHighTrust diff =
− 1.615; SE = 0.407; p = 0.001;MSlotVSLowTrust diff = − 0.961;
SE = 0.353; p = 0.015, see Fig. 2). We found no main effect of
drug (Drug, F(1, 271) = 0.174, p = 0.677), and no interaction
with drug (Drug × Facial Trust, F(2, 271) = 0.381, p = 0.684).
Thus, while facial trustworthiness had an effect on the initial
investments, MPH did not alter those patterns.
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All trials
The second set of analyses used all the task trials in a mixed-
model approach. We examined whether MPH could impact
the initial beliefs about the facial trust level of a partner, the
effect of experience with a partner, and their interaction.
Across all trials, facial trust level impacted investments
(Facial Trust, χ2(2) = 10.286, p = 0.006). However, this main
effect was driven by the difference between human faces and
slot machines: high facial trustworthiness versus slot machine
(M diff = 0.814; SE = 0.272; p = 0.008) and low facial trust-
worthiness versus slot machine (M diff = 0.718; SE = 0.289;
p = 0.035). There were no significant differences between the
two levels of human facial trustworthiness (M diff = 0.095;
SE = 0.191; p = 0.871).
There was a trend for the impact of drug administration on
investments as a function of facial trustworthiness across the
entire experiment (Drug × Facial Trust, χ2(2) = 5.160,
p = 0.076).
Over the course of the experiment, participants learned
about the likelihood of game partners to reciprocate their in-
vestment. This was reflected in a main effect of reciprocity on
amount invested, where participants invested more with game
partners who were high reciprocators than with low-
reciprocating partners (Reciprocation, χ2(1) = 111.431,
p < 0.001). However, knowledge about the likelihood of re-
ciprocation was not affected by drug administration (Drug ×
Reciprocation, χ2(1) = 0.003, p = 0.956).
Next, we explored the drug effects on the interaction be-
tween facial trustworthiness and reciprocation. This key three-
way interaction was significant (Drug × Facial Trust ×
Reciprocation, χ2(2) = 8.109, p = 0.017), and it was driven
by the different drug effects for slot machine partners, on the
one hand, and the human partners, on the other, when com-
paring high versus low reciprocation likelihood (High Trust vs
Slot Machine, χ2(1) = 6.287, p = 0.037, and Low Trust vs Slot
Machine, χ2(1) = 5.892, p = 0.037 respectively, see Fig. 3).
There was no difference between the high and low trust game
partners (χ2(1) = 0.007, p = 0.936). Specifically, we found a sig-
nificant simple main effect: for low reciprocators, investments
with the low trust partners were lower on drug as compared
with placebo (χ2(1) = 7.476, p = 0.038), while this effect was
missing for the slot machine and for the high trust partners
(Slot Machine, χ2(1) = 1.673, p = 0.677, and High Trust,
χ2(1) = 1.335, p = 0.677). In contrast, for high reciprocators,
investments with high trust, low trust, and slot machines
showed no effects of drug (High Trust, χ2(1) = 0.117, p =
0.733; Low Trust, χ2(1) = 1.889, p = 0.677; Slot Machine,
χ2(1) = 2.869, p = 0.452). Together, this indicates that MPH
decreased investment amounts specifically with low trust so-
cial partners that did not reciprocate often.
The interaction between facial trustworthiness and recipro-
cation likelihood was significant both under placebo (Placebo:
Facial Trust × Reciprocation, χ2(1) = 415.74, p < 0.001), and
under MPH (MPH: Facial Trust × Reciprocation, χ2(1) =
517.79, p < 0.001).
Finally, we found that participants invested on average about
50% of their allocated amount, and investments with ostensi-
ble human game partners were on average higher than those
with slot machines (M diff = 0.800; SE = 0.263; p = 0.004).
Mean investments per each experimental condition are report-
ed in Table 1.
Order effects
Given that participants played the Trust Game twice across
two different sessions, we examined whether order effects
could account for the drug effects outlined above. When con-
trolling for drug administration order, the significance and
interpretation of reported effects were not altered, although
we found a main effect of the order of drug administration
(Order, χ2(1) = 4.726, p = 0.030). To further ensure the reli-
ability of the task results, we compared only the first session
across groups, thus eliminating the order factor. Here, we
again observe a reliable effect of Drug × Facial Trust ×
Reciprocation (χ2(2) = 11.885, p = 0.003). Moreover, the sim-
ple main effect of a decrease in investments with low recipro-
cators who were low on trustworthiness was significant
(χ2(1) = 5.7019, p = 0.017).
Discussion
The current study illustrates how investment behavior in a
well-characterized economic exchange task, the Trust Game,
can be altered by a catecholamine challenge.
Our results are consistent with several previous findings
regarding investment behavior in the Trust Game.
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Fig. 2 The figure illustrates the mean investments (± SE) with the three
levels of facial Trust Game partners, in the first trial of the Trust Game
only
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Participants invested on average slightly less than half of their
endowment with their game partners, in line with previous
literature (Fehr and Schmidt 1999; Camerer 2003; Camerer
and Fehr 2006). As expected, in the first interaction with each
game partner, the partner’s facial trustworthiness influenced
investments, specifically, game partners with high facial
trustworthiness receivedmore money on this initial interaction
than did those with low facial trustworthiness (Van ‘t Wout and
Sanfey 2008; Chang et al. 2010). However, the influence of
facial features on investment amount was not significant
across all game interactions with a given partner, that is, the
influence of the partner’s facial features diminishes over time
on average. Additionally, the behavior of the game partners, in
terms of how likely they are to reciprocate the participant’s
trust, influences investments: high-reciprocating game part-
ners receive larger investments than low-reciprocating part-
ners (Singer et al. 2004; King-Casas et al. 2005), demonstrat-
ing that participants can learn these probabilities across the
task. Furthermore, investments in slot machine partners were
lower than investments with the human game partners.
The main focus of this study was on how administration of
MPH would impact these effects. Contrary to our hypothesis,
when compared with placebo, MPH did not alter investment
patterns on the first encounter with a partner. There was also
no effect of drug on investment amount as a function of the
likelihood that a particular partner would reciprocate.
However, drug administration did interact with facial trust-
worthiness and with the probability of reciprocation. We
found a selective effect of drug on investment behavior to-
wards those partners with both low facial trustworthiness
and a low probability of reciprocation. Specifically, players
invested less in low-reciprocating, low trustworthy-looking
game partners when given MPH compared with placebo.
This study is among the few to investigate how catechol-
amines may alter decision-making in social contexts, and is
novel in focusing on iterated trust behavior. Our finding that
MPH affects investment when playing with a particular set of
game partners, namely those who were low in trust and low in
reciprocation, is supported by previous work examining the
role of MPH in social processing. For example, Campbell-
Meiklejohn and colleagues (2012a), demonstrated that
administration of MPH influenced behavior in a social
rating task, finding an increased salience of the social
judgments of others. Here, the authors theorized that MPH is
likely to increase interest and motivation during cognitive
tasks, via the mechanism of increasing extracellular dopamine
levels in the striatum. The idea that MPH can increase selec-
tive motivation is further supported by several studies
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Table 1 Mean invested amounts
across drug, reciprocation
probability, and facial trust
(means and standard deviations)
Mean investment amounts with each game partner (euro) Drug administration
Placebo MPH
High reciprocation High Trust 6.50 (2.18) 6.74 (1.74)
Low Trust 6.51 (1.69) 6.16 (2.07)
Slot Machine 5.03 (2.66) 4.73 (1.98)
Low reciprocation High Trust 3.00 (1.76) 2.69 (1.47)
Low Trust 3.29 (1.55) 2.58 (1.12)
Slot Machine 2.79 (1.63) 3.12 (1.69)
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showing how acute MPH (and amphetamine) administration
can facilitate the identification of facial expression of emo-
tions in healthy subjects (Wardle and De Wit 2012; Hysek
et al. 2014). In a similar vein, though only examined in chil-
dren with ADHD, MPH also enhanced empathy and theory of
mind abilities (Maoz et al. 2014). More evidence of specific
effects of elevated DA in a social context comes from
Eisenegger et al. (2014), who showed that L-DOPA adminis-
tration affects participants’ investment choices as a function of
endogenous dopamine levels, as assessed by the DAT1 geno-
type. Finally, in a related study, Pedroni et al. (2014), showed
that a single dose of L-DOPA can lower investments in a
social economic game, though only when participants are
not under the threat of punishment. These latter findings are
explained as a consequence of a shift in focus: participants
become more focused on personal monetary gains under L-
DOPA, when the social norms cannot be enforced.
Notably in our study, MPH had an effect on partners who
were lowest in terms of both facial trustworthiness and
reciprocation. Interestingly, a previous study found that a high
dose of MPH (60 mg) increased the recognition of sad and
fearful faces particularly (Hysek et al. 2014), and also in-
creased anxiety levels compared with placebo. Other research
has found that MPH led participants to enhance the recogni-
tion of anger and fear in subjects with ADHD (Williams et al.
2008), and also resulted in participants more often
misclassifying an emotion as anger (Dolder et al. 2018).
Relatedly, a similar negative bias in the processing of emo-
tionally laden stimuli was reported under higher doses of am-
phetamine (Wardle and De Wit 2012). As both MPH and
amphetamine stimulate the DA and NE systems, our findings
suggest that elevated MPHmay be linked to a negative bias in
processing of socially relevant stimuli, but specifically in the
context of negative experience.
One mechanism that could underlie this observed drug ef-
fect is that of an increase in confirmation bias (Doll et al.
2011). Confirmation bias refers to the persistence of behaviors
that are in line with the described, but not with the experi-
enced, contingencies (Nickerson 1998). That is, experiences
which are congruent with prior beliefs receive higher weight
than experiences which are incongruent with prior beliefs or
expectations. For instance, during election season, people are
more likely to believe positive information about their favorite
candidates, while at the time disregarding negative informa-
tion about them. Thus, this account, as per our hypothesis,
would predict that under MPH, partners with low facial trust-
worthiness and low reciprocation would evoke a decrease in
investments, while those with high facial trustworthiness and
high reciprocation would elicit an increase in investments,
both relative to placebo. Our results do exhibit the former
pattern, though not the latter. One possible explanation for
the lack of confirmation bias in the positive direction is that
there may be a ceiling effect in investments with this latter
group, namely, that investments in this game seldom reach
the maximum level, especially as Bhigh reciprocators^ only
reciprocate in approximately 75% of the interactions. We in
fact did find a difference in investment amounts, with more
being sent to the high facial trustworthiness, high reciproca-
tion group under MPH than placebo, in accordance with a
confirmation bias account, though this difference did not
reach significance. The selective reduction in investments on-
ly for the low facial trust low reciprocation game partners
suggests an increase in the salience of prior beliefs on the
subsequent value-based learning.
An alternative explanation for our results could be a change
in risk perception as a function of drug administration. In
clinical populations, MPH has been linked to riskier decision
tendencies compared with healthy individuals (Rahman et al.
2006; DeVito et al. 2008; Shiels et al. 2009). In healthy par-
ticipants, Campbell-Meiklejohn et al. (b) showed that
MPH altered risk-taking in a gambling task as a function of
the size of the stake. In particular, with small stakes (similar in
magnitude to those used in the current study), under MPH
participants demonstrated a trend towards increased risk aver-
sion, that is, a tendency not to gamble. This is consistent with
the behavior of the low facial trust low-reciprocating game
partners in our study. However, in their study, MPH also led
to an increase in risky behavior with larger stakes, suggesting
a more complex relationship between MPH and risk attitudes.
Given that MPH has quite a high frequency of use not only in
clinical population (ADHD), but also in healthy individuals
(Smith and Farah 2011), it is important to investigate how this
drug impacts higher cognitive functions, specifically in social
settings. In this iterated version of the Trust Game, each part-
ner is encountered multiple times. Thus, participants are mo-
tivated to learn about how likely it is that an investment with
another player yields a monetary gain, while at the same time
updating beliefs about their original assessment of the trust-
worthiness of each of the partners.
We believe some notable strengths of the current study are
that we utilized a double-blind, placebo-controlled, within-
subject design, and that we replicated many of previous
Trust Game findings which have been conducted without
pharmacological intervention.
Despite participants playing the game itself twice, and
therefore, potentially possessing advance knowledge of
the task, particularly when playing for the second time,
we nonetheless found robust effects of MPH on trust
behavior.
Overall, we showed that MPH administration impacts
decision-making in a well-understood economic task, spe-
cifically for social game partners who both trigger a low
trust belief and who also seldom reciprocate trust over
time. We interpret these findings as evidence that MPH
can enhance the salience of socially relevant prior beliefs,
possibly via a confirmation bias mechanism.
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